Lantern Pharma (NASDAQ: LTRN) announced that the U.S. Patent and Trademark Office has issued a Notice of Allowance for a patent application covering methods of selecting and treating patients with ovarian, primary liver, kidney and thyroid cancers using its investigational therapy LP-184 (zirdafulven) based on a three-gene biomarker signature. The allowed claims cover the use of elevated expression of PTGR1, PTPN14 and ASPH to identify patients who may benefit from treatment with LP-184.
The company’s RADR® artificial intelligence platform helped identify the biomarker signature used in the patent, supporting the development of a precision medicine approach for LP-184. Lantern reported a 45% disease control rate among patients treated at or above the effective therapeutic dose in its Phase 1a trial and plans to advance LP-184 into multiple Phase 1b/2 precision oncology studies during 2026 while continuing to expand its intellectual property portfolio. For more details, see the full press release at https://ibn.fm/LRGUo.
This patent allowance is significant because it validates Lantern’s AI-driven approach to identifying biomarkers that predict patient response, potentially increasing the success rate of LP-184 in clinical trials by targeting only those most likely to benefit. The three-gene signature may also serve as a diagnostic tool to guide treatment decisions, moving oncology toward more personalized medicine. By securing intellectual property around this method, Lantern strengthens its competitive position in the precision oncology space and provides a foundation for future biomarker-based therapies.
The allowance comes as Lantern prepares to initiate multiple Phase 1b/2 studies in 2026, which will test LP-184 in biomarker-selected patient populations. The company’s RADR platform continues to be a key differentiator, enabling the discovery of such signatures efficiently. For investors, this development underscores the potential of Lantern’s pipeline and its commitment to data-driven drug development. More company updates can be found at the newsroom: https://ibn.fm/LTRN.
Lantern Pharma is a clinical-stage precision oncology company leveraging AI, machine learning, and its proprietary RADR® platform to transform the development of cancer therapies. Its clinical pipeline includes LP-184, LP-284 (a TC-NER targeting compound in hematologic and solid tumors), and LP-300, which is being evaluated in the HARMONIC Phase 2 trial in never-smoker patients with relapsed advanced lung adenocarcinoma following TKI treatment. LP-184 is also being developed for pediatric CNS cancers through Starlight Therapeutics, Lantern’s wholly owned CNS-focused subsidiary. Additionally, withZeta.ai, Lantern’s multi-agentic AI co-scientist platform, is now commercially available as a subscription-based research platform, representing a new revenue stream.
